Myriad Genetics Inc (MYGN) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of Myriad Genetics Inc $1.16, price $4.14, upside -72.0%, quality 42 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Myriad Genetics Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
60‑month range $2.86 – $36.66 · fair‑value band $0.8600 – $1.73 · the $4.14 price screens above the $1.16 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.
Follow Myriad Genetics in your weekly email
Every Wednesday you see whether Myriad Genetics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics.
Show more
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; FirstGene; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; University of Texas M.D. Anderson Cancer Center; Mayo Foundation for Medical Education and Research; Children's Medical Center in Boston; Institut Curie and INSERM; and Eurobio Scientific SA. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
Stock analysis
Myriad Genetics Inc (MYGN) currently trades at $4.14, while our model-based Fair Value estimate is $1.16, implying the stock looks roughly 256.9% overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.
Scenario range: $0.8600 (bear) to $1.73 (bull), the price of $4.14 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 42/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Myriad Genetics Inc reported revenue of $825M in FY2025 versus $691M in FY2021, a compound +4.5%/yr. Reported net income was −$366M in FY2025.
Key figures
Market cap $429M · P/S ratio 0.77 · EPS (TTM) $−4.31 · Net margin −44.4% · Return on equity −23.5% · Return on assets (EBIT) −14.0% · Operating margin −21.4% · Revenue (TTM) $557M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 34 out of 100 (medium confidence).
What moves the price
The share trades about 49% below its 52-week high and 45% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −72%, MYGN screens richer than that median.
Fair Value models
Bear $0.8600Fair Value $1.16Bull $1.73
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.16/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−1.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.2%
Start year 2020 (pandemic). Over 10 years: +1.3% a year
Revenue growth 30 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.5%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−35.0% (2020) → −8.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 143 stocks
Beats the industry median on 3/10 measures
Overall it trails its industry peers.
Valuation
Quality Score42 · Below median
Fair Value upside−72% · Bottom 25%
Profitability
Return on assets−8% · Bottom 25%
Net margin (TTM)−41% · Bottom 25%
Operating margin (TTM)−21% · Bottom 25%
Growth and dividend
Revenue growth−21% · Bottom 25%
Balance sheet
Debt / equity0.33× · Above median
Valuation Multiplesvs Diagnostics & Research median · lower = cheaper
P/B1.17× · Cheaper than median
P/S (TTM)0.77× · Cheaper than median
PEG1.40× · Cheaper than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)0· sector 28
PAST (return on equity)0· sector 8
HEALTH (low debt)84· sector 95
DIVIDEND (yield)0· sector 30
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Myriad Genetics Inc (MYGN) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of $1.16 versus a price of $4.14, about −72% upside (overvalued).
What is the fair value of MYGN?
Our model-based fair value for Myriad Genetics Inc is $1.16 (as of Sep 23, 2026), built from audited fundamentals. The current price: $4.14.
What is the quality score of MYGN?
Myriad Genetics Inc has a Quality Score of 42/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Myriad Genetics Inc (MYGN)?
Our model-based price target is the fair value of $1.16 (as of Sep 23, 2026) from 1 valuation models. Cautious scenario $0.8600, optimistic scenario $1.73. It is a calculation from audited fundamentals, not an analyst target.
What is the Myriad Genetics Inc stock forecast for 2026?
Our models put fair value at $1.16, about −72% upside versus a price of $4.14 (overvalued). Cautious scenario $0.8600, optimistic scenario $1.73. The calculation is refreshed regularly with new filings.
What is the revenue of Myriad Genetics Inc (MYGN)?
Myriad Genetics Inc reported trailing-twelve-month revenue of about $557M (latest available figure, as of Sep 23, 2026).
What is the intrinsic value of Myriad Genetics Inc (MYGN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Myriad Genetics Inc it is $1.16 per share (as of Sep 23, 2026), against a price of $4.14. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Myriad Genetics Inc stock overvalued or undervalued in 2026?
As of Sep 23, 2026, MYGN trades above its calculated fair value: price $4.14, fair value $1.16, a gap of about −72% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of MYGN?
No. The price is what the market pays today ($4.14); the fair value is what the company's own numbers justify ($1.16). For Myriad Genetics Inc the two are $2.98 per share apart. That gap is exactly why we show both numbers side by side.
How much is Myriad Genetics Inc worth?
The market values Myriad Genetics Inc at about $429M (market capitalisation, as of Sep 23, 2026). Per share that is $4.14; our models calculate a fair value of $1.16 per share.
What do the bullish and bearish scenarios say about MYGN?
Our models span a range for Myriad Genetics Inc: cautious scenario $0.8600, base $1.16, optimistic $1.73 per share (as of Sep 23, 2026, price $4.14). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of MYGN?
The PEG ratio of Myriad Genetics Inc is 1.40 (P/E divided by earnings growth, as of Sep 23, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Myriad Genetics Inc (MYGN)?
Balance-sheet figures for Myriad Genetics Inc (as of Sep 23, 2026): return on equity −23.5%, debt of 0.33 per unit of equity. They feed the Quality Score of 42/100, which measures business quality independently of the share price.
How far is MYGN from its 52-week high?
Myriad Genetics Inc trades at $4.14, about 49% below its 52-week high of $8.18 and 45% above the low of $2.86 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of $1.16 is for.
Which stocks are comparable to Myriad Genetics Inc?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Lonza Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Myriad Genetics Inc stock attractive at the current price?
The data as of Sep 23, 2026: price $4.14, calculated fair value $1.16 (−72%), Quality Score 42/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of MYGN calculated?
We run Myriad Genetics Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $1.16, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. Myriad Genetics Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Myriad Genetics Inc (MYGN)?
The closing price on Sep 24, 2026 was $4.14. Our model-based fair value is $1.16, about −72% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Myriad Genetics Inc right now?
The price sits above even our optimistic bull case ($1.73). The favourable scenario is already priced in. Weak quality (42/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($0.8600 to $1.73) leaves room in how you read the outcome.
Key figures of Myriad Genetics Inc
How large is the market capitalisation of Myriad Genetics Inc (MYGN)?
The market capitalisation of Myriad Genetics Inc is $429M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Myriad Genetics Inc (MYGN)?
The price-to-sales ratio of Myriad Genetics Inc is 0.77 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Myriad Genetics Inc (MYGN)?
Earnings per share at Myriad Genetics Inc are $−4.31. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Myriad Genetics Inc (MYGN)?
The net margin of Myriad Genetics Inc is −44.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Myriad Genetics Inc (MYGN)?
The return on equity (ROE) of Myriad Genetics Inc is −23.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Myriad Genetics Inc (MYGN)?
On an EBIT basis the return on assets of Myriad Genetics Inc is −14.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Myriad Genetics Inc (MYGN)?
The operating margin of Myriad Genetics Inc is −21.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Myriad Genetics Inc (MYGN)?
Revenue at Myriad Genetics Inc is growing −20.8% versus a year earlier (3y avg +6.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Myriad Genetics Inc (MYGN) generate?
The free cash flow of Myriad Genetics Inc is −$13.8M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Myriad Genetics Inc (MYGN) carry?
The net debt of Myriad Genetics Inc is $60.2M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Myriad Genetics Inc in the live analysis
One click puts Myriad Genetics Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 23, 2026